Janux Therapeutics (JANX) FCF Margin (2021 - 2025)
Historic FCF Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 129.49%.
- Janux Therapeutics' FCF Margin rose 3844100.0% to 129.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 713.97%, marking a year-over-year decrease of 4241200.0%. This contributed to the annual value of 417.2% for FY2024, which is 2313800.0% up from last year.
- As of Q3 2025, Janux Therapeutics' FCF Margin stood at 129.49%, which was up 3844100.0% from 513.9% recorded in Q3 2024.
- Over the past 5 years, Janux Therapeutics' FCF Margin peaked at 1423.68% during Q1 2021, and registered a low of 1468.68% during Q2 2023.
- Its 5-year average for FCF Margin is 538.07%, with a median of 536.28% in 2021.
- Per our database at Business Quant, Janux Therapeutics' FCF Margin crashed by -22099000bps in 2022 and then surged by 13549800bps in 2024.
- Quarter analysis of 5 years shows Janux Therapeutics' FCF Margin stood at 687.5% in 2021, then grew by 29bps to 491.0% in 2022, then rose by 14bps to 423.24% in 2023, then dropped by -21bps to 513.9% in 2024, then soared by 75bps to 129.49% in 2025.
- Its FCF Margin was 129.49% in Q3 2025, compared to 513.9% in Q3 2024 and 113.7% in Q2 2024.